Edwards Lifesciences Q2 Earnings Call Highlights
Edwards Lifesciences (NYSE:EW) reported Q2 TAVR growth with stable global average selling prices and raised full-year TAVR sales guidance to $4.75B to $5.0B (8% to 9%). Q2 transcatheter mitral and tricuspid therapies were $195.9M (+44.8% YoY). The company also lifted TMTT guidance to $760M to $780M and projected Q3 sales $1.63B to $1.71B and adjusted EPS $0.71 to $0.77.
How this was made
The 30-second read
Why it matters
Raised 2026 TAVR and TMTT guidance, along with specific product and regulatory milestones (CE Mark for SAPIEN M3 RESILIA, U.S. approval for ECLIPTIS, expected PASCAL approvals/launch timing), provide actionable inputs for reforecasting and positioning. However, margin and tax-rate headwinds and the still-pending CMS policy finalization add uncertainty.
Market read
Traders can update 2026 revenue and EPS models using the raised TAVR and TMTT guidance and the provided Q3 sales and adjusted EPS range, while monitoring CMS coverage timing and tax/margin headwinds.
What to watch
The CMS national coverage determination is pending with a September final memo; PROGRESS trial impact is expected minimal in 2026, so traders may discount longer-dated catalysts versus near-term guidance.
Background
The piece summarizes Edwards Lifesciences' Q2 earnings call, focusing on structural heart (TAVR, TMTT) and surgical product updates, plus margin, tax, and Q3 outlook.
Ticker impact
Edwards raised full-year TAVR sales growth guidance to 8% to 9% and expects TAVR sales of $4.75B to $5.0B, plus higher TMTT guidance.
Moderately positive bias for the next few sessions as traders reprice 2026 revenue and margin expectations around the raised guidance.
The article provides concrete, company-specific 2026 guidance updates (TAVR and TMTT) and a Q3 sales/EPS outlook, which are direct inputs to valuation and positioning. Offsetting items include FX and tax-rate headwinds, but the net effect is still an upward guide.
Market effects
Structural heart and transcatheter valve peers may see read-across from Edwards' TAVR durability data, SAPIEN X4-S updates, and coverage-policy expectations.
Limited direct regional impact; guidance references stable global ASPs and U.S. versus ex-U.S. TAVR growth similarity.
Global structural heart demand and reimbursement policy expectations could influence broader medtech sentiment, but the article is primarily company-specific.
Counterpoint
Tax-rate headwinds (Pillar Two and California R&D credit limits) and FX-driven margin pressure could cap upside despite higher top-line guidance.
Key entities
- companyEdwards Lifesciences
Structural heart and critical care monitoring company; raised TAVR and TMTT guidance and provided Q3 outlook.
- regulatorCMS (draft policy memo)
Draft CMS policy for TAVR coverage discussed; final policy memo expected in September.
- productsPASCAL, EVOQUE, SAPIEN M3
TMTT and TAVR platforms referenced for adoption, clinical evidence, and regulatory progress.
